[Influence of long-used staphylokinase derivative on hemoagglutinative and fibrinolytic systems].
This study was aimed to explore the influence of staphylokinase derivative (SAKD) on the hemoagglutinative and fibrinolytic systems, and to determine the safety of the staphylokinase derivative in application. The normal and model rats each 30 were divided into normal saline, SAKD and rSAK groups. The hemorrhage, bleeding time (BT), blood platelet count (BPC), activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), fibrinogen (Fg), D-dimer (D-D), plasminogen (PLG) and plasmin inhibitor activity (PI) were detected before and after the administration with staphylokinase derivative 0.5 mg/kg body weight, once three days for consecutive 15 days. The results indicated that one case of normal rats with SAKD and two cases of high fat diet model group had mild hemorrhage, all of which showed automatic hemostasis; and 3 cases in rSAK group had mild hemorrhage. And the platelet counting, D-D, PLG and PI in all groups did not significantly change. The rats of high fat diet group treated with SAKD showed the significant extension of APTT, PT and TT times, and the decrease of Fg time (p < 0.05). All the experimental results demonstrated that the influence of SAKD on the hemagglutination of the normal animals was lower, however, which can improve the high-hemagglutination status of the rats with high fat diet. It is concluded that the SAKD at the dosage of this study has the higher safety, which can alleviate the high hemagglutination symptoms of the rats with high fat diet.
Wang
Yuan-Yuan
YY
Institute of Basic Medical Sciences, Academy of Military Medical Sciences, Beijing, China.
Long
Min-Hui
MH
Wang
Jin-Feng
JF
Zhu
He
H
Wang
Min
M
Zou
Min-Ji
MJ
Liu
Shen
S
Xu
Tao
T
Wang
Jia-Xi
JX
Xu
Dong-Gang
DG
D000818:Animals; D004041:Dietary Fats; D005338:Fibrin Fibrinogen Degradation Products; D005342:Fibrinolysis / Q000187:drug effects*; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000494:pharmacology; D006384:Hemagglutination / Q000187:drug effects*; D006487:Hemostasis; D008297:Male; D008666:Metalloendopeptidases / Q000494:pharmacology; D010314:Partial Thromboplastin Time; D010976:Platelet Count; D011517:Prothrombin Time; D051381:Rats; D017208:Rats, Wistar; D011993:Recombinant Fusion Proteins / Q000009:adverse effects* / Q000494:pharmacology*; D013918:Thrombin Time; D015912:Thrombolytic Therapy
D004041:Dietary Fats; D005338:Fibrin Fibrinogen Degradation Products; D005343:Fibrinolytic Agents; D011993:Recombinant Fusion Proteins; C036309:fibrin fragment D; D008666:Metalloendopeptidases; C022653:auR protein, Staphylococcus aureus